“If you're thinking about urology, then what I would do is get exposure as early as possible,” says Curtis A. Pettaway, MD.
In this video, Society of Urologic Oncology’s 2021 Huggins Medalrecipient, Curtis A. Pettaway, MD, advises medical students and young urologists on navigating the field. Pettaway is a professor of urology at the University of Texas MD Anderson Cancer Center in Houston.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.